Loading page
Loading page
Loading substance route
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Recreational use is rare due to the drug's very long duration of action (>40 hours) and apparent lack of euphoric effects. Misuse potential is considered limited compared to other NMDA receptor antagonists.
| Species | Route | Value |
|---|---|---|
| mouse | oral | 437 mg/kg |
| rat | oral | 328 mg/kg |
Blood clots and heart failure have been reported as severe but rare adverse effects, primarily documented in clinical use among elderly patients with dementia.
Cystitis has been reported as a less common adverse effect in clinical settings.
Psychosis is listed as a severe but rare side effect. Hallucinations and confusion are more common adverse effects (≥1% of patients) in clinical populations. At supratherapeutic recreational doses, dissociative effects may produce psychotomimetic symptoms.
Memantine was first synthesized and patented by Eli Lilly and Company in 1963, originally developed as a potential anti-diabetic agent. However, the compound proved ineffective at lowering blood sugar and the project stalled. Nearly a decade later, in 1972, researchers discovered that memantine…
Approved pharmaceutical available by prescription. Generic and brand name formulations have been marketed since at least 2010, including products from multiple labellers.
FDA-approved in 2013 for the management of Alzheimer's disease. Not a scheduled controlled substance under the Controlled Substances Act. Available only by prescription; generic and brand name formulations are marketed.
Approved and marketed as a prescription pharmaceutical across EU member states. Brand name products including Axura have been available since at least 2016.
19 sources cited
